应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00874 白云山
休市中 11-22 16:08:13
17.700
-0.360
-1.99%
最高
18.100
最低
17.660
成交量
238.60万
今开
18.080
昨收
18.060
日振幅
2.44%
总市值
287.76亿
流通市值
38.94亿
总股本
16.26亿
成交额
4,273万
换手率
1.08%
流通股本
2.20亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
白云山:子公司复方感冒灵胶囊获得《药品补充申请批准通知书》
证券日报 · 11-21 20:35
白云山:子公司复方感冒灵胶囊获得《药品补充申请批准通知书》
白云山(00874)子公司获得药品补充申请批件
智通财经 · 11-21 18:39
白云山(00874)子公司获得药品补充申请批件
白云山最新公告:子公司中一药业获得复方感冒灵胶囊药品补充申请批件
证券之星 · 11-21 18:31
白云山最新公告:子公司中一药业获得复方感冒灵胶囊药品补充申请批件
白云山(00874.HK)分公司何济公药厂新增生产线和生产范围获批
阿斯达克财经 · 11-20
白云山(00874.HK)分公司何济公药厂新增生产线和生产范围获批
白云山(00874):何济公药厂《药品生产许可证》变更
智通财经 · 11-20
白云山(00874):何济公药厂《药品生产许可证》变更
白云山(600332.SH)分公司何济公药厂新增生产线和生产范围获批
智通财经 · 11-20
白云山(600332.SH)分公司何济公药厂新增生产线和生产范围获批
净利润持续下滑,白云山面临业绩与合规双重压力
中访网财经 · 11-19
净利润持续下滑,白云山面临业绩与合规双重压力
白云山(00874)附属明兴药业收到广东省药品监督管理局核准签发的《药品生产许可证》
智通财经 · 11-18
白云山(00874)附属明兴药业收到广东省药品监督管理局核准签发的《药品生产许可证》
白云山子公司《药品生产许可证》变更
格隆汇 · 11-18
白云山子公司《药品生产许可证》变更
白云山,“千亿市值”梦难圆
经理人杂志 · 11-18
白云山,“千亿市值”梦难圆
白云山(00874)出现大手买入76万股,成交价$18.28,涉资1.389千万
阿斯达克财经 · 11-18
白云山(00874)出现大手买入76万股,成交价$18.28,涉资1.389千万
白云山净利润“凉凉”:王老吉、金戈双拳难敌市场冲击,理财借款两不误?
华夏时报 · 11-16
白云山净利润“凉凉”:王老吉、金戈双拳难敌市场冲击,理财借款两不误?
长城证券:白云山业绩符合预期,费用效率改善
财中社 · 11-15
长城证券:白云山业绩符合预期,费用效率改善
Norges Bank减持白云山(00874)54万股 每股作价约19.12港元
智通财经网 · 11-13
Norges Bank减持白云山(00874)54万股 每股作价约19.12港元
南向资金11月12日净买入白云山52.60万股 连续5日增持
市场透视 · 11-13
南向资金11月12日净买入白云山52.60万股 连续5日增持
白云山:关于该事项的说明详见本公司2023年年度报告的有关内容
证券之星 · 11-12
白云山:关于该事项的说明详见本公司2023年年度报告的有关内容
白云山:分公司枸橼酸西地那非片获得《药品补充申请批准通知书》
证券日报 · 11-06
白云山:分公司枸橼酸西地那非片获得《药品补充申请批准通知书》
Norges Bank减持白云山(00874)80.8万股 每股作价约18.36港元
智通财经 · 11-06
Norges Bank减持白云山(00874)80.8万股 每股作价约18.36港元
白云山(00874)分公司获得药品补充申请批件
智通财经 · 11-06
白云山(00874)分公司获得药品补充申请批件
白云山最新公告:分公司获得药品补充申请批件
证券之星 · 11-06
白云山最新公告:分公司获得药品补充申请批件
暂无数据
公司概况
公司名称:
白云山
所属市场:
SEHK
上市日期:
--
主营业务:
广州白云山医药集团股份有限公司从事制药和保健行业。该公司的业务分部包括:大南药分部、大健康分部、大商业分部和大医疗分部。大南药分部从事研究、开发、制造和销售中西成药、化学原料药、天然药物、生物医药和化学原料药中间体业务。大健康分部从事研究、开发、制造和销售饮料、食品、保健品等产品。大商业分部从事批发、零售和进出口西药、中药和医疗器械业务。大医疗分部从事医疗服务、中医养生、现代养老以及医疗器械产业。
发行价格:
--
{"stockData":{"symbol":"00874","market":"HK","secType":"STK","nameCN":"白云山","latestPrice":17.7,"timestamp":1732262893011,"preClose":18.06,"halted":0,"volume":2386000,"delay":0,"floatShares":220000000,"shares":1625790949,"eps":2.674991,"marketStatus":"休市中","marketStatusCode":7,"change":-0.36,"latestTime":"11-22 16:08:13","open":18.08,"high":18.1,"low":17.66,"amount":42728840,"amplitude":0.024363,"askPrice":17.7,"askSize":16000,"bidPrice":17.68,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":2.25788709502495,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":878140800000,"adjPreClose":18.06,"dividendRate":0.069614,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":1.6301820626266756,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"白云山","latestPrice":28.06,"timestamp":1732258800000,"preClose":28.93,"halted":0,"volume":7827882,"delay":0,"premium":"-41.17"}},"requestUrl":"/m/hq/s/00874/tweets","defaultTab":"tweets","newsList":[{"id":"2485249804","title":"白云山:子公司复方感冒灵胶囊获得《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2485249804","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485249804?lang=zh_cn&edition=full","pubTime":"2024-11-21 20:35","pubTimestamp":1732192537,"startTime":"0","endTime":"0","summary":"证券日报网讯11月21日晚间,白云山发布公告称,近日,公司子公司广州白云山中一药业有限公司收到国家药品监督管理局签发的《药品补充申请批准通知书》,药品通用名称为复方感冒灵胶囊。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411213246959970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1606","BK1197","BK1521","00874","BK1515"],"gpt_icon":0},{"id":"2485465687","title":"白云山(00874)子公司获得药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2485465687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485465687?lang=zh_cn&edition=full","pubTime":"2024-11-21 18:39","pubTimestamp":1732185562,"startTime":"0","endTime":"0","summary":"智通财经APP讯,白云山 发布公告,该公司子公司广州白云山中一药业有限公司收到国家药品监督管理局签发的《药品补充申请批准通知书》。中一药业于2024年10月22日向国家药监局递交本药品补充申请,于2024年10月25日获得受理。中一药业本次获得复方感冒灵胶囊《药品补充申请批准通知书》,有利于本公司优化资源配置,继续保持稳定的生产能力,满足市场需求。本次获得《药品补充申请批准通知书》,对本公司当期业绩无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","600332","BK1197","BK0196","BK0012","BK1515","BK0070","BK0183","BK0239","BK0096","BK1521","BK0175","BK0188","00874","BK1606","BK1191","BK0028"],"gpt_icon":0},{"id":"2485655944","title":"白云山最新公告:子公司中一药业获得复方感冒灵胶囊药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2485655944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485655944?lang=zh_cn&edition=full","pubTime":"2024-11-21 18:31","pubTimestamp":1732185097,"startTime":"0","endTime":"0","summary":"白云山公告,子公司中一药业收到国家药监局签发的《药品补充申请批准通知书》,批准复方感冒灵胶囊的药品上市许可持有人由“广州白云山奇星药业有限公司”变更为“广州白云山中一药业有限公司”。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100030087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK1515","00874","BK0070","BK1606","BK0028","BK0239","BK1521","BK1191","600332","BK0196","BK0188","BK1197","BK0096","BK0012","BK0183","BK0097"],"gpt_icon":0},{"id":"2484169628","title":"白云山(00874.HK)分公司何济公药厂新增生产线和生产范围获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484169628","media":"阿斯达克财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484169628?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:42","pubTimestamp":1732092120,"startTime":"0","endTime":"0","summary":"白云山(00874.HK) (600332.SH) 公布,其分公司何济公药厂近日收到广东省药品监督管理局核准签发的《药品生产许可证》,同意何济公药厂新增生产线和生产范围,并通过药品生产质量管理规范检查。(jl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-20 16:25。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200312162542031_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200312162542031_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398220/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0183","BK1197","BK0070","BK0097","BK0096","BK0175","BK0012","BK0188","600332","BK1521","BK1606","BK1515","BK0239","BK0028","BK1191","BK0196","00874"],"gpt_icon":0},{"id":"2484660351","title":"白云山(00874):何济公药厂《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2484660351","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484660351?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:39","pubTimestamp":1732091948,"startTime":"0","endTime":"0","summary":"智通财经APP讯,白云山(00874)发布公告,近日,广州白云山医药集团股份有限公司(以下简称“本公司”)分公司广州白云山医药集团股份有限公司白云山何济公制药厂(以下简称“何济公药厂”)收到广东省药品监督管理局核准签发的《药品生产许可证》,同意何济公药厂新增生产线和生产范围,并通过药品生产质量管理规范检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1197","BK0012","BK1515","BK0175","BK0070","BK0188","BK0196","BK0097","BK0239","600332","BK1521","BK0028","BK0183","BK0096","BK1606","00874"],"gpt_icon":0},{"id":"2484006165","title":"白云山(600332.SH)分公司何济公药厂新增生产线和生产范围获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2484006165","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484006165?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:23","pubTimestamp":1732091039,"startTime":"0","endTime":"0","summary":"智通财经APP讯,白云山(600332.SH)发布公告,公司分公司广州白云山医药集团股份有限公司白云山何济公制药厂(简称“何济公药厂”)收到广东省药品监督管理局核准签发的《药品生产许可证》,同意何济公药厂新增生产线和生产范围,并通过药品生产质量管理规范检查。同意何济公药厂在生产地址“广州市荔湾路49号”生产车间“荔湾制造部”新增生产线“喷雾剂生产线”、新增生产范围“喷雾剂”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","BK0196","BK1191","BK1521","BK0096","BK1606","BK0070","BK0175","BK0183","BK0239","00874","BK0188","600332","BK0012","BK0028","BK1197","BK1515"],"gpt_icon":0},{"id":"2484547279","title":"净利润持续下滑,白云山面临业绩与合规双重压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2484547279","media":"中访网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484547279?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:38","pubTimestamp":1731983885,"startTime":"0","endTime":"0","summary":"近日,白云山发布了2024年三季度报告。财报显示,公司2024年前三季度实现营业收入590.6亿元,同比增长1.50%,实现归属净利润31.59亿元,同比下滑16.68%。 据了解,白云山....","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OwBpI1AjagaaVhyabIb06cd_Mf0qtuurUi7tNT-pijgjoAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OwBpI1AjagaaVhyabIb06cd_Mf0qtuurUi7tNT-pijgjoAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241119A02UV500","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241119A02UV500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["00874"],"gpt_icon":0},{"id":"2484964020","title":"白云山(00874)附属明兴药业收到广东省药品监督管理局核准签发的《药品生产许可证》","url":"https://stock-news.laohu8.com/highlight/detail?id=2484964020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484964020?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:05","pubTimestamp":1731927941,"startTime":"0","endTime":"0","summary":"智通财经APP讯,白云山(00874)发布公告,近日,该公司全资子公司广州白云山明兴制药有限公司(以下简称“明兴药业”)收到广东省药品监督管理局核准签发的《药品生产许可证》,同意明兴药业新增生产车间、生产线和生产范围,并通过药品生产质量管理规范符合性检查。本次明兴药业新增生产车间、生产线和生产范围,并通过药品生产质量管理规范符合性检查,有利于其优化产能,提升智能化、数字化、绿色化水平,继续保持稳定的生产能力,满足市场需求。本次获得《药品生产许可证》,对公司当期业绩无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1197","BK0012","BK1515","BK0175","BK0070","BK0188","BK0196","BK0097","BK0239","600332","BK1521","BK0028","BK0183","BK0096","BK1606","00874"],"gpt_icon":0},{"id":"2484628848","title":"白云山子公司《药品生产许可证》变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2484628848","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484628848?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:51","pubTimestamp":1731927084,"startTime":"0","endTime":"0","summary":"格隆汇11月18日丨白云山公告,近日,广州白云山医药集团股份有限公司全资子公司广州白云山明兴制药有限公司收到广东省药品监督管理局核准签发的《药品生产许可证》,同意明兴药业新增生产车间、生产线和生产范围,并通过药品生产质量管理规范符合性检查。本次获得《药品生产许可证》,对本公司当期业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118185125abcc4df1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118185125abcc4df1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1197","BK1515","00874","BK1521","BK1606","BK1191"],"gpt_icon":0},{"id":"2484748316","title":"白云山,“千亿市值”梦难圆","url":"https://stock-news.laohu8.com/highlight/detail?id=2484748316","media":"经理人杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484748316?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:30","pubTimestamp":1731922200,"startTime":"0","endTime":"0","summary":"以下文章来源于于见专栏,作者虞尔湖","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OF4NYhXzmk1rE8LZQzTX1vYqrRE5BYqjxzpxrfawreWN8AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OF4NYhXzmk1rE8LZQzTX1vYqrRE5BYqjxzpxrfawreWN8AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241118A077YB00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241118A077YB00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1606","BK1191","BK1515","BK1521","00874","BK1197"],"gpt_icon":0},{"id":"2484614986","title":"白云山(00874)出现大手买入76万股,成交价$18.28,涉资1.389千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614986","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614986?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:29","pubTimestamp":1731914940,"startTime":"0","endTime":"0","summary":"[大手成交]白云山(00874)在下午03:29出现大手买入,成交量为76万,成交价为港币$18.28,涉资1.389千万。至目前为止,股价跌0.111%,今日最高价为$18.38,而最低价为$18.0,总成交量为223.82万股,总成交金额港币$4.075千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2411187817/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00874","600332","BK0096","BK0183","BK1515","BK1521","BK0196","BK0188","BK1191","BK0028","BK0175","BK0239","BK0070","BK1197","BK1606","BK0097","BK0012"],"gpt_icon":0},{"id":"2483594542","title":"白云山净利润“凉凉”:王老吉、金戈双拳难敌市场冲击,理财借款两不误?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483594542","media":"华夏时报","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483594542?lang=zh_cn&edition=full","pubTime":"2024-11-16 18:18","pubTimestamp":1731752310,"startTime":"0","endTime":"0","summary":"本报(chinatimes.net.cn)记者于娜 见习记者 张斯文 北京报道在此前发布的三季报中,广州白云山医药集团股份有限公司(下称“白云山”,600332.SH)的净利润大幅下滑引发了市场关注。公司给出的理由是“受宏观经济波动、市场竞争及行业政策等因素影响”,而在同样的环境下,不少可比同类公司反而取得了不错的业绩增长。显...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OevKaDpxVp3DI-XUQ0JJAD7VEP3HV4c3GLaVJO6PavaF4AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OevKaDpxVp3DI-XUQ0JJAD7VEP3HV4c3GLaVJO6PavaF4AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241116A06POP00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241116A06POP00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["00874"],"gpt_icon":0},{"id":"2483396894","title":"长城证券:白云山业绩符合预期,费用效率改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2483396894","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483396894?lang=zh_cn&edition=full","pubTime":"2024-11-15 11:11","pubTimestamp":1731640272,"startTime":"0","endTime":"0","summary":"财中社11月15日电白云山发布2024年三季度报告,2024年前三季度公司实现营收590.6亿元,同比+1.5%;实现归母净利润31.6亿元,同比-16.7%;实现扣非净利润28.6亿元,同比-17.0%。其中,2024年第三季度公司实现营收180.2亿元,同比-1.1%;实现归母净利润6.1亿元,同比-37.8%;实现扣非归母净利润5.1亿元,同比-38.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411153240833564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","00874","BK1606","BK1521","BK1191","BK1197"],"gpt_icon":0},{"id":"2483008466","title":"Norges Bank减持白云山(00874)54万股 每股作价约19.12港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008466","media":"智通财经网","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483008466?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:41","pubTimestamp":1731494460,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示,11月8日,Norges Bank减持白云山(00874)54万股,每股作价19.1161港元,总金额约为1032.27万港元。减持后最新持股数目为1715.3万股,最新持股比例为7.80%。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvxpfh7952949.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvxpfh7952949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","BK0028","BK0096","BK1521","BK0175","BK0070","BK0012","BK0097","BK0183","BK0188","BK1515","00874","BK1191","BK1606","BK0239","BK1197","600332"],"gpt_icon":0},{"id":"2483094920","title":"南向资金11月12日净买入白云山52.60万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2483094920","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483094920?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461410,"startTime":"0","endTime":"0","summary":"11月12日, 南向资金增持白云山52.60万股,连续5日增持。截止当日收盘,港股通共持有白云山11878.46万股,占流通股54.00%。港股通增持金额前五个股分别为中芯国际、建设银行、中升控股、安踏体育、中国神华。白云山近5个交易日上涨1.07%,港股通累计增持189.20万股;近20个交易日上涨0.42%,港股通累计增持783.20万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093045abbb7e4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093045abbb7e4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00874","BK1606","BK1197","BK1191","600332","BK1521","BK1515"],"gpt_icon":0},{"id":"2482774076","title":"白云山:关于该事项的说明详见本公司2023年年度报告的有关内容","url":"https://stock-news.laohu8.com/highlight/detail?id=2482774076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482774076?lang=zh_cn&edition=full","pubTime":"2024-11-12 19:00","pubTimestamp":1731409234,"startTime":"0","endTime":"0","summary":"证券之星消息,白云山11月12日在投资者关系平台上答复投资者关心的问题。关于该事项的说明详见本公司2023年年度报告的有关内容。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200031013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK1515","00874","BK0070","BK1606","BK0028","BK0239","BK1521","BK1191","600332","BK0196","BK0188","BK1197","BK0096","BK0012","BK0183","BK0097"],"gpt_icon":0},{"id":"2481606896","title":"白云山:分公司枸橼酸西地那非片获得《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2481606896","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481606896?lang=zh_cn&edition=full","pubTime":"2024-11-06 20:41","pubTimestamp":1730896893,"startTime":"0","endTime":"0","summary":"证券日报网讯11月6日晚间,白云山发布公告称,近日,公司分公司广州白云山医药集团股份有限公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》,药品通用名称为枸橼酸西地那非片。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411063231396322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","BK1606","BK1197","BK1191","BK1515","00874"],"gpt_icon":0},{"id":"2481605338","title":"Norges Bank减持白云山(00874)80.8万股 每股作价约18.36港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481605338","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481605338?lang=zh_cn&edition=full","pubTime":"2024-11-06 20:24","pubTimestamp":1730895898,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,11月1日,Norges Bank减持白云山(00874)80.8万股,每股作价18.3615港元,总金额约为1483.6092万港元。减持后最新持股数目为1975.7万股,最新持股比例为8.98%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1606","BK1515","BK0097","BK0070","BK0012","BK1521","BK0188","600332","BK0175","BK0196","BK0096","00874","BK0028","BK0183","BK0239","BK1191","BK1197"],"gpt_icon":0},{"id":"2481765826","title":"白云山(00874)分公司获得药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2481765826","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481765826?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:53","pubTimestamp":1730890406,"startTime":"0","endTime":"0","summary":"智通财经APP讯,白云山 发布公告,近日,公司分公司广州白云山医药集团股份有限公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》。白云山制药总厂本次获得桑菊感冒颗粒《药品补充申请批准通知书》,完善了该药品的安全性信息,有利于提升该产品的市场竞争力。本次获得上述药品补充申请批准通知书,对公司当期业绩无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0239","BK0097","BK1606","BK0028","BK0188","600332","BK0012","BK1521","BK0175","BK1191","00874","BK0196","BK1515","BK1197","BK0096","BK0070"],"gpt_icon":0},{"id":"2481678471","title":"白云山最新公告:分公司获得药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2481678471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481678471?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:10","pubTimestamp":1730887840,"startTime":"0","endTime":"0","summary":"白云山公告,分公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》。药品通用名称为枸橼酸西地那非片。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600031446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0196","BK1191","BK1521","BK0096","BK1606","BK0070","BK0175","BK0183","BK0239","00874","BK0188","600332","BK0012","BK0028","BK1197","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gybys.com.cn","stockEarnings":[{"period":"1week","weight":-0.021},{"period":"1month","weight":-0.08},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.16},{"period":"1year","weight":-0.1447},{"period":"ytd","weight":-0.1349}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0737},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0334},{"period":"1year","weight":0.0736},{"period":"ytd","weight":0.128}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州白云山医药集团股份有限公司从事制药和保健行业。该公司的业务分部包括:大南药分部、大健康分部、大商业分部和大医疗分部。大南药分部从事研究、开发、制造和销售中西成药、化学原料药、天然药物、生物医药和化学原料药中间体业务。大健康分部从事研究、开发、制造和销售饮料、食品、保健品等产品。大商业分部从事批发、零售和进出口西药、中药和医疗器械业务。大医疗分部从事医疗服务、中医养生、现代养老以及医疗器械产业。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.011967},{"month":2,"riseRate":0.692308,"avgChangeRate":0.062033},{"month":3,"riseRate":0.62963,"avgChangeRate":0.059521},{"month":4,"riseRate":0.666667,"avgChangeRate":0.087941},{"month":5,"riseRate":0.555556,"avgChangeRate":0.049452},{"month":6,"riseRate":0.481481,"avgChangeRate":0.021437},{"month":7,"riseRate":0.407407,"avgChangeRate":-0.018239},{"month":8,"riseRate":0.37037,"avgChangeRate":-0.039061},{"month":9,"riseRate":0.407407,"avgChangeRate":-0.011257},{"month":10,"riseRate":0.407407,"avgChangeRate":0.002825},{"month":11,"riseRate":0.428571,"avgChangeRate":0.007844},{"month":12,"riseRate":0.538462,"avgChangeRate":0.027564}],"exchange":"SEHK","name":"白云山","nameEN":"BAIYUNSHAN PH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"白云山,00874,白云山股票,白云山股票老虎,白云山股票老虎国际,白云山行情,白云山股票行情,白云山股价,白云山股市,白云山股票价格,白云山股票交易,白云山股票购买,白云山股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}